Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

NBTXR3 · NSC-158931

Other · developed by Nanobiotix

Phase 1/2 Most advanced trial (none active)
NBTX Developer
1 Registered trials

What is NBTXR3?

NBTXR3 is an agent injected into the prostate gland before intensity-modulated radiation therapy (IMRT), and it is studied in prostate cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
NSC-158931
Drug type
Other
Therapy area
Oncology
Developer
Nanobiotix (NBTX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
3C4Z4KG52T

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02805894 Phase 1/2 Prostate Cancer Terminated NBTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Prostate Cancer

More from Nanobiotix

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the NBTX page.

Follow NBTX, the company behind NBTXR3

See NBTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NBTX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.